INCR vs. RENB, IMAB, SKYE, SYRS, CTMX, CRVO, SGMT, CYBN, RAPT, and RPTX
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Renovaro (RENB), I-Mab (IMAB), Skye Bioscience (SKYE), Syros Pharmaceuticals (SYRS), CytomX Therapeutics (CTMX), CervoMed (CRVO), Sagimet Biosciences (SGMT), Cybin (CYBN), RAPT Therapeutics (RAPT), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical preparations" industry.
InterCure (NASDAQ:INCR) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
8.3% of InterCure shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
InterCure has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
InterCure has higher revenue and earnings than Renovaro. Renovaro is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
InterCure received 3 more outperform votes than Renovaro when rated by MarketBeat users.
InterCure's return on equity of 0.00% beat Renovaro's return on equity.
In the previous week, Renovaro had 3 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Renovaro and 1 mentions for InterCure. InterCure's average media sentiment score of 0.59 beat Renovaro's score of 0.34 indicating that InterCure is being referred to more favorably in the media.
Summary
InterCure beats Renovaro on 9 of the 12 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
